Citations

3636 total record number
147 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by type of cell/animal/assay/protein/research or publication.

Page 1 out of 728

Combined Effects of Lactobacillus rhamnosus and Egg Oral Immunotherapy in a Mouse Model of Egg Allergy

Kim, BG;Kim, JN;Jang, AS;Shin, M;
Product: Cholera Toxin (AZIDE-FREE) from Vibrio cholerae
Female, 3-week-old C3H/HeJ mice were sensitized by intragastric administration of 1 mg of ovomucoid (OM; Sigma-Aldrich, St Louis, MO, USA) with 10 µg of cholera toxin (List Biological Laboratories, Campbell, CA, USA) as an adjuvant weekly for 6 weeks Cached
PubMed ID: 32400134

Oligodendrocyte ARNT2 expression is altered in models of MS

Becquart, P;Johnston, J;Vilariño-Güell, C;Quandt, JA;
Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer
All mice received pertussis toxin (List Biologicals, Campbell, CA) intraperitoneally that day and 2 days later
PubMed ID: 32439712

Inactivation of Rho GTPases by Burkholderia cenocepacia Induces a WASH-Mediated Actin Polymerization that Delays Phagosome Maturation

Walpole, GFW;Plumb, JD;Chung, D;Tang, B;Boulay, B;Osborne, DG;Piotrowski, JT;Catz, SD;Billadeau, DD;Grinstein, S;Jaumouillé, V;
Product: Toxin B from Clostridium difficile
C. difficile Toxin B (TcdB) List Biological Laboratories Cat#155A
PubMed ID: 32492429

A stable protocol for the fabrication of transplantable human oral mucosal epithelial cell sheets for clinical application

Kasai, Y;Takagi, R;Kobayashi, S;Owaki, T;Yamaguchi, N;Fukuda, H;Sakai, Y;Sumita, Y;Kanai, N;Isomoto, H;Kanetaka, K;Ohki, T;Asahina, I;Nagai, K;Nakao, K;Takeda, N;Okano, T;Eguchi, S;Yamato, M;
Product: Cholera Toxin (AZIDE-FREE) from Vibrio cholerae
stol-Myers Squibb, NY, USA), 0.25 μM hydrocortisone (Kowa, Nagoya, Japan), 140 mU/mL insulin (Lilly, IN, USA), 2.0 nM 3,3′,5-Triiodo-l-thyronine (MP Biomedicals, CA, USA), 1.0 nM cholera toxin (List Biological Laboratories, CA, USA), 0.2 μM recombinant hEGF (Higeta-Shoyu, Tokyo, Japan), 0.1 mM sulbactam, 0.2 mM ampicillin (Pfizer, NY, USA), and 14 μM streptomycin (Meiji Seika Pharma, T ... stol-Myers Squibb, NY, USA), 0.25 μM hydrocortisone (Kowa, Nagoya, Japan), 140 mU/mL insulin (Lilly, IN, USA), 2.0 nM 3,3′,5-Triiodo-l-thyronine (MP Biomedicals, CA, USA), 1.0 nM cholera toxin (List Biological Laboratories, CA, USA), 0.2 μM recombinant hEGF (Higeta-Shoyu, Tokyo, Japan), 0.1 mM sulbactam, 0.2 mM ampicillin (Pfizer, NY, USA), and 14 μM streptomycin (Meiji Seika Pharma, T; - Dohme, NJ, USA), 0.3 μM amphotericin B (Bristol-Myers Squibb, NY, USA), 0.25 μM hydrocortisone (Kowa, Nagoya, Japan), 140 mU/mL insulin (Lilly, IN, USA), 2.0 nM 3,3′,5-Triiodo-l-thyronine (MP Biomedicals, CA, USA), 1.0 nM cholera toxin (List Biological
PubMed ID: 31988998

Ocular Surface Ectoderm Instigated by WNT inhibition and BMP4

Kobayashi, Y;Hayashi, R;Shibata, S;Quantock, A;Nishida, K;
Product: Cholera Toxin (AZIDE-FREE) from Vibrio cholerae
0.4 μg/mL hydrocortisone succinate (Wako), 2 nM 3,3′,5-triiodo-l-thyronine sodium salt (MP Biomedicals, Santa Ana, CA), 1 nM cholera toxin (List Biological Laboratory, Campbell, CA), 2.25 μg/mL bovine transferrin HOLO form (Thermo Fisher Scientific), 2 mM L-glutamine, 0.5% insulin transferrin selenium (Thermo Fisher Scientific), and 1% penicillin-streptomycin. Cells were washed in phosphate-buffered saline